Harker LA, Gent M.The use of agents that modify platelet function in the management of thrombotic disorders. In Colman RW, Hirsh J, Marder VJ , Salzman EW, eds. Hemostasis and Thrombosis, 2nd ed. Philadelphia : JB Lippincott, 1987 , pp 1438-1456.
2.
Antiplatelet Trialists' Collaboration.Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J296:320-333, 1988.
3.
O'Reilly RATherapeutic modalities for thrombotic disorders. In Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis , 2nd ed. Philadelphia: JB Lippincott, 1987 , pp 1367-1372.
4.
Rosenberg RDBiochemistry of heparin antithrombin interactions, and the physiologic role of this natural anticoagulant mechanism. Am J Med87(3B):2S-9S, 1989.
5.
Rowland M., Riegelman S., Harris PA, et al. Absorption kinetics of aspirin in man following oral administration of an aqueous solution. J Pharm Sci61:379, 1972.
6.
Ali M., McDonald JWD, Thiessen JJ, Coates PEPlasma acetylsalicylate and salicylate and enteric-coated aspirin . Stroke11:9-13, 1980.
7.
Levy G.Clinical pharmacokinetics of aspirin. Pediatrics62:867, 1978.
8.
Jakubowski JA , Stampfer MJ, Vaillancourt R., et al. Cumulative anti-platelet effect of low-dose enteric-coated aspirin. Br J Haematol60:635-642, 1985.
9.
Cohen A.Fecal blood loss and plasma salicylate study of salicylic acid and aspirin . J Clin Pharmacol19:242-247, 1979.
10.
Fromm D.Salicylate and gastric mucosal damage. Pediatrics62:938, 1978.
11.
UK-TIA Study Group.United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: Interim results. Br Med J296:316-320, 1988.
12.
Roth GJ, Majerus PW The mechanism of the effect of aspirin on human platelet . I. Acetylation of a particulate fraction protein. J Clin Invest56:624, 1975.
13.
Roth GJ, Stanford N., Majerus PW Acetylation of prostaglandin synthetase by aspirin. Proc Natl Acad Sci USA73:3073, 1975.
14.
Burch JW, Stanford N., Majerus PW Inhibition of platelet prostaglandin synthetase by oral aspirin . J Clin Invest61:314, 1978.
15.
Gorman RR, Fitzpatrick FA, Miller OVA selective thromboxane synthetase inhibitor blocks the cyclic AMP lowering activity of PGH2. Biochem Biophys Res Commun79:305, 1977.
16.
Weiss HJ, Aledort LM, Kochwa S.The effect of salicylates on the hemostatic properties of platelet in man . J Clin Invest47:2169, 1968.
17.
Wong LT, Zawidzka Z., Thomas RBEffect of acetylsalicylic acid, sulphinpyrazone and their combination of collagen-induced platelet aggregation in guinea pigs. Pharmacol Res Commun10:939, 1979.
18.
Packham MAStages in the interaction of platelets with collagen. Thromb Haemost36: 269, 1976.
19.
Packham MA, Kinlough-Rathbone RL, Reimers HJ, et al. Mechanisms of platelet aggregation independent of adenosine diphosphate. In Silver MJ, Smith JB, Kocsis JJ, eds. Prostaglandins in Hematology. New York: Spectrum Publishing, 1977 , p 247.
20.
TschoppThB. Aspirin inhibits platelet aggregation on, but not adhesion to, collagen fibrils: An assessment of platelet adhesion and deposited platelet mass by morphometry and 51Cr-labelling. Thromb Res11:619, 1977.
21.
Patrignani P., Fiblabozzi P., Patrono C.Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest69:1366, 1982.
22.
Karwande SV , Weksler BB, Gay WA, et al. Effect of preoperative antiplatelet drugs on vascular prostacyclin synthesis. Ann Thorac Surg43:318-322, 1987.
23.
Hirsh J.Progress review: The relationship between dose of aspirin, side-effects and antithrombotic effectiveness. Stroke16:1-4, 1985.
24.
Mills DCB.Platelet aggregation and the adenylate cyclase system. In Mills DCB, Pareti FI, eds. Platelets and Thrombosis. London : Academic Press, 1977, p 63.
25.
Bunag RD, Doublas R., Imai RMInfluence of a pyrimidopyrimidine derivative on deamination of adenosine by blood. Circ Res15:83, 1964.
26.
Ally AI, Manku MS, Horrobin DG, et al. Dipyridamole: A possible potent inhibitor of thromboxane A2 synthetase in vascular smooth muscle. Prostaglandins14:607, 1977.
27.
Emmons PR, Harrison MJG, Honour AJ, et al. Effect of dipyridamole on human platelet behaviour. Lancet2:603, 1965.
28.
Zucker MB, Peterson J.Effect of acetylsalicylic acid, other nonsteroidal antiinflammatory agents and dipyridamole on human blood platelets. J Lab Clin Med76:66, 1970.
29.
Harker LAPlatelet survival time: Its measurement and use. In Spaet TH, ed. Progress in Hemostasis and Thrombosis, vol 4. New York : Grune & Stratton, 1978, pp 321-347.
30.
FitzGerald GADipyridamole. N Engl J Med316:1247-1257, 1987.
31.
Aberg M., Hedner U., Bergentz SEThe antithrombotic effect of dextran. Scand J Haematol34:61, 1979.
32.
Weiss HJThe effect of clinical dextran on platelet aggregation, adhesion and ADP release in man: In vivo and in vitro studies. J Lab Clin Med69:37, 1967.
33.
Aberg M., Hedner U., Bergentz SEEffect of dextran on factor VIII (antihemophilic factor) and platelet function . Ann Surg189:182-243, 1979.
34.
Muzaffar TZ , Stalker AL, Bryce WAJ, et al. Dextrans and fibrin morphology. Nature238: 288-290, 1972.
35.
Dhall TZ, Bryce WAJ, Dhall DPEffects of dextran on the molecular structure and tensile behaviour of human fibrin. Thromb Haemost35:737-745, 1976.
36.
Aberg M., Bergentz SE, Hedner U.The effect of dextran on the lysability of ex vivo thrombi. Ann Surg181:342-345, 1975.
37.
Shoenfeld NA , Elldrup-Jorgensen J., Connolly R., et al. The effect of low molecular weight dextran on platelet deposition onto prosthetic materials . J Vasc Surg5:76-82, 1987.
38.
Ring J., Messmer K.Incidence and severity of anaphylactoid reactions to colloid volume substitutes . Lancet1:466, 1977.
39.
Defreyn G., Bernat A., Delebassee D., Maffrand J-P.Pharmacology of ticlopidine: A review. Semin Thromb Hemost15(2):159-166, 1989.
40.
Feliste R., Delebassee D., Simon MF, et al. Broad spectrum anti-platelet activity of ticlopidine and PCR 4099 involves the suppression of the effects of released ADP. Thromb Res48:403-415, 1987.
41.
Gachet C., Stierle A., Bouloux C., et al. The thienopyridine PCR 4099 inhibits the ADP aggregation pathway of human platelets by interfering with the binding of fibrinogen to the glycoprotein IIb-IIIa complex [abstr]. Thromb Haemost58:211, 1987.
42.
Ellis DJ, Roe RL, Bruno JJ, et al. The effects of ticlopidine hydrochloride on bleeding time and platelet function in man [abstr]. Thromb Haemost46:1973, 1981.
43.
Hass WK, Easton JD, Adams HP Jr, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med321:501-507, 1989.
44.
Gent M., Easton JD, Hachinski VC, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet1:1215-1220, 1989 .
45.
Panak E., Maffrand J-P., Picard-Fraire C., et al. A promise for the prevention and treatment of thrombosis and its complications. Haemostasis13(Suppl 1):1-52, 1983.
46.
Palareti G. , Poggi M., Torricelli P., et al. Long-term effects of ticlopidine on fibrinogen and haemorheology in patients with peripheral arterial disease . Thromb Res52:621-629, 1988.
47.
Arcan JC, Panak E.Ticlopidine in the treatment of peripheral occlusive arterial disease . Semin Thromb Hemost15:167-170, 1989.
48.
Balsano F., Coccheri S., Libretti A., et al. Ticlopidine in the treatment of intermittent claudication: A 21-month double-blind trial. J Lab Clin Med114:84-91, 1989.
49.
Szilagyi DE, Elliott JP, Hageman JH, et al. Biologic fate of autogenous vein implants as arterial substitutes: Clinical, angiographic and histopathologic observations in femoropopliteal operations for atherosclerosis. Ann Surg178:232-246, 1973.
50.
Hagen PO, Wang ZG, Mikat EM, et al. Antiplatelet therapy reduces aortic intimal hyperplasia distal to small-diameter vascular prostheses (PTFE) in nonhuman primates. Ann Surg195:328-339, 1982.
51.
McCann RL, Hagen PO, Fuchs JCA.Aspirin and dipyridamole decrease intimal hyperplasia in experimental vein grafts. Ann Surg191:238-243, 1980.
52.
Metke MP, Lie JT, Fuster V., et al. Reduction of intimal thickening in canine coronary bypass vein grafts with dipyridamole and aspirin. Am J Cardiol43:1144-1148, 1979.
53.
Clowes AW, Karnovsky MJFailure of certain antiplatelet drugs to affect myointimal thickening following arterial injury. Lab Invest36:452-458, 1977.
54.
Bomberger RA , DePalma RG, Ambrose TA, et al. Aspirin and dipyridamole inhibit endothelial healing. Arch Surg117:1459-1464, 1982 .
55.
Unni KK, Kottke BA, Titus JL, et al. Pathologic changes in aortocoronary saphenous vein grafts. Am J Cardiol34:526-532, 1974.
56.
Fuster V., Chesebro JHRole of platelets and platelet inhibitors in aortocoronary artery vein-graft disease. Circulation73:227-232, 1986.
57.
Goldman MD, Simpson D., Hawker RJ, et al. Aspirin and dipyridamole reduced platelet deposition on prosthetic femoro-popliteal grafts in man. Ann Surg198:713-716, 1983.
58.
Pumphrey CW , Chesebro JH, Dewanjee MK, et al. In vivo quantitation of platelet deposition on human peripheral arterial bypass grafts using indium-111—labeled platelets: Effect of dipyridamole and aspirin. Am J Cardiol51:796-801, 1983.
59.
Stratton JR , Ritchie JLFailure of ticlopidine to inhibit deposition of indium-111I-labeled platelets on Dacron prosthetic surfaces in humans. Circulation69:677-683, 1984.
60.
Stratton JR , Ritchie JLThe effects of sulfinpyrazone on platelet deposition on Dacron vascular grafts in man. Am Heart J109:453-457, 1985.
61.
Stratton JR , Ritchie JLReduction of indium-111 platelet deposition on Dacron vascular grafts in humans by aspirin plus dipyridamole . Circulation73:325-330, 1986.
62.
Goldman M., Norcott HC, Hawker RJ, et al. Platelet accumulation on mature Dacron grafts in man. Br J Surg69:S38-S40, 1982.
63.
Mayer JE, Lindsay WG, Castaneda W., et al. Influence of aspirin and dipyridamole on patency of coronary artery bypass grafts. Ann Thorac Surg31:204-210, 1981.
64.
Chesebro JH , Clements IP, Fuster V., et al. A platelet-inhibitor-drug trial in coronary-artery bypass operations: Benefit of perioperative dipyridamole and aspirin therapy on early postoperative vein-graft patency. N Engl J Med307:73-78, 1982.
65.
Chesebro JH , Fuster V., Elveback LR, et al. Effect of dipyridamole and aspirin on late vein-graft patency after coronary bypass operations. N Engl J Med310:209-214, 1984.
66.
Lorenz RL, Schacky CV, Weber M., et al. Improved aortocoronary bypass patency by low-dose aspirin (100 mg daily): Effects on platelet aggregation and thromboxane formation. Lancet1:1261-1264, 1984.
67.
Brown BG, Cukingnan RA, DeRouen T., et al. Improved graft patency in patients treated with platelet-inhibiting therapy after coronary bypass surgery. Circulation72:138-146, 1985.
68.
Rajah SM, Salter MCP, Donaldson DR, et al. Acetvlsalicvlic acid and dipyridamole improve the early patency of aorto-coronary bypass grafts: A double-blind, placebo-controlled, randomized trial. J Thorac Cardiovasc Surg90:373-377, 1985.
69.
Goldman S., Copeland J., Moritz T., et al. Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: Results of a Veterans Administration Cooperative StudyCirculation77:1324-1332, 1988.
70.
Pfisterer M. , Jockers G., Regenass S., et al. Trial of low-dose aspirin plus dipyridamole versus anticoagulants for prevention of aortocoronary vein graft occlusion . Lancet2:1-6, 1989.
71.
Pantely GA, Goodnight SH, Rahimtoola SH, et al. Failure of antiplatelet and anticoagulant therapy to improve patency of grafts after coronary-artery bypass: A controlled, randomized study . N Engl J Med301:962-966, 1979.
72.
McEnany MT, Salzman EW, Mundth ED, et al. The effect of antithrombotic therapy on patency rates of saphenous vein coronary artery. J Thorac Cardiovasc Surg83:81-89, 1982.
73.
Sharma Gvrk , Khuri SF, Josa M., et al. The effect of antiplatelet therapy on saphenous vein coronary artery bypass graft patency . Circulation68 (Suppl II):218-221, 1983.
74.
Brooks N., Wright J., Sturridge M., et al. Randomised placebo-controlled trial of aspirin and dipyridamole in the prevention of coronary vein graft occlusion. Br Heart J53:201-207, 1985.
75.
Sethi GK, Copeland JG, Goldman S., et al. Implications of preoperative administration of aspirin in patients undergoing coronary artery bypass grafting. J Am Coll Cardiol15: 15-20, 1990.
76.
Green RM, Roedersheimer R., DeWeese JAEffects of aspirin and dipyridamole on expanded polytetrafluoroethylene graft patency. Surgery92:1016-1026, 1982 .
77.
Goldman M., Hall C., Dykes J., et al. Does 111indium-platelet deposition predict patency in prosthetic arterial grafts? Br J Surg70:635-638, 1983.
78.
Kohler TR, Kaufman JL, Kacoyanis G., et al. Effect of aspirin and dipyridamole on the patency of lower extremity bypass grafts. Surgery96:462-466, 1984.
79.
Clyne CAC , Archer TJ, Atuhaire LK, et al. Random control trial of a short course of aspirin and dipyridamole (Persantin) for femorodistal grafts. Br J Surg74:246-248, 1987.
80.
McCollum C. , Alexander C., Kenchington G., et al. Antiplatelet drugs in femoro-popliteal vein bypass: A multicentre trial. J Vasc Surg (in press).
81.
Hennekens CH , Buring JE, Sandercock P., et al. Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease. Circulation80:749-756, 1989.
82.
Kretschmer G., Pratschner T., Prager M., et al. Antiplatelet treatment prolongs survival after carotid bifurcation endarterectomy: Analysis of the clinical series followed by a controlled trial. Ann Surg211:317-322, 1990.
83.
Rutherford RB, Jones DN, Bergentz SE, et al. The efficacy of dextran-40 in preventing early postoperative thrombosis following difficult lower extremity bypass . J Vasc Surg1: 765-772, 1984.
84.
Kretschmer G., Wenzl E., Piza E., et al. The influence of anticoagulant treatment on the probability of function in femoropopliteal vein bypass surgery: Analysis of a clinical series (1970 to 1985) and interim evaluation of a controlled clinical trial. Surgery102:453-459, 1987.
85.
Kretschmer G., Schemper M., Ehringer H., et al. Influence of postoperative anticoagulant treatment on patient survival after femoropopliteal vein bypass surgery. Lancet1:797, 1988.
86.
Arfvidsson B., Lundgren F., Drott C., et al. Influence of coumarin treatment on patency and limb salvage after peripheral arterial reconstructive surgery . Am J Surg159:556-560, 1990.
87.
Hirsh J., Poller L., Deykin D., et al. Optimal therapeutic range for oral anticoagulants. Chest95:5S-11S, 1989.
88.
Hull R., Hirsh J., Jay R., et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med307:1676-1681, 1982.
89.
Turpie ACG , Gunstensen J., Hirsh J., et al. Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. Lancet1:1241, 1988.
90.
Saour JN, Sieck JO, Mamo LAR, Gallus ASTrial of different intensities of anticoagulation in patients with prosthetic heart valves. N Engl J Med322:428, 1990.
91.
Baxter BT, Bergman RT, McCarthy WJ, et al. Prospective assessment of antithrombotic therapy following primary below-knee prosthetic bypass. J Vasc Surg (in press).
92.
Salzman EW, Hirsh J.Prevention of venous thromboembolism. In Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis, 2nd ed. Philadelphia: JB Lippincott, 1987 , pp 1252-1265.
93.
Clagett GP, Genton E., Salzman EW, Antithrombotic therapy in peripheral vascular disease. Chest95:128S-139S, 1989.
94.
Collins GJ Jr, Kimball DB, Rich NM, et al. Heparin utilization during arterial revascularization. Am Surg44:753-757, 1978.
95.
Effeney DJ, Goldstone J., Chin D., et al. Intraoperative anticoagulation in cardiovascular surgery. Surgery90:1068-1074, 1981.
96.
Weksler BB, Lewin M.Anticoagulation in cerebral ischemia. Stroke14:658-663, 1983.
97.
Bousser MG, Eschwege E., Haguenau M., et al. "AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke14:5, 1983.
98.
CanadianCooperative Group. A randomized trial of aspirin and sulfinpyrazone in threatened stroke. N Engl J Med299:53, 1978.
99.
Fields WS, Lemak N., Frankowski RF, et al. Controlled trial of aspirin in cerebral ischemia. Stroke8:301-314, 1977.
100.
Sorensen PS , Pedersen H., Marquardsen J., et al. Acetylsalicylic acid in the prevention of stroke in patients with reversible cerebral ischemic attack. A Danish Cooperative Study. Stroke14:15, 1983.
101.
A. SwedishCooperative Study. High-dose acetylsalicylic acid after cerebral infarction. Stroke18:325-334, 1987.
102.
Ramirez-Lassepas M., Cipolle RJMedical treatment of transient ischemic attacks: Does it influence mortality?Stroke19:397-400, 1988.
103.
Whisnant JP , Sandok BA, Sundt TMCarotid endarterectomy for unilateral carotid system transient cerebral ischemia. Mayo Clin Proc58:171-175, 1983.
104.
NorthAmerican Symptomatic Carotid Endarterectomy Study Group. Carotid endarterectomy: Three critical evaluations. Stroke18:987-989, 1987.
105.
Stratton JR , Zierler E., Kazmers A.Platelet deposition at carotid endarterectomy sites in humans. Stroke18:722-727, 1987.
106.
Findlay JM , Lougheed WM, Gentili F., et al. Effect of perioperative platelet inhibition on postcarotid endarterectomy mural thrombus formation . J Neurosurg63:693-698, 1985.
107.
Fields WS, Lemak NA, Frankowski RF, Hardy RJControlled trial of aspirin in cerebral ischemia. II. Surgical group. Stroke9:309, 1978.
108.
Clagett GP , Rich NM, McDonald PT, et al. Etiologic factors for recurrent carotid artery stenosis. Surgery93:313, 1983.
109.
Cossman D. , Callow AD, Stein A., et al. Early restenosis after carotid endarterectomy . Arch Surg113:275, 1978.
110.
Reunanen A. , Takkunen H., Aromass A.Prevalence of intermittent claudication and its effect on mortality. Acta Med Scand211:249-256, 1982.
111.
Criqui MH, Fronek A., Barrett-Connor E., et al. The prevalence of peripheral arterial disease in a defined population . Circulation71:510-515, 1985.
112.
Jelnes R., Gaardsting O., Jensen KH, et al. Fate in intermittent claudication: Outcome and risk factors . Br Med J293:1137-1140, 1986 .
113.
Steering Committee of the Physicians' Health Study Research Group.Preliminary report: Findings from the aspirin component of the ongoing physicians' health study. N Engl J Med318:262-264, 1988.
114.
Peto R., Gray R., Collins R., et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J296:313-316, 1988.
115.
Relman ASAspirin for the primary prevention of myocardial infarction [editorial] . N Engl J Med318:245-246, 1988.
116.
Boissel JP , Peyrieux JC, Destors JMIs it possible to reduce the risk of cardiovascular events in subjects suffering from intermittent claudication of the lower limbs?Thromb Haemost62:681-685, 1989.
117.
Wilentz JR , Sanborn TA, Haudenschild CC, et al. Platelet accumulation in experimental angioplasty: Time course and relation to vascular injury. Circulation75:636, 1987.
118.
Cunningham DA, Kumar B., Siegel BA, et al. Aspirin inhibition of platelet deposition at angioplasty sites: Demonstration by platelet scintigraphy . Radiology151:487, 1984.
119.
Schwartz L. , Bourassa MG, Lesperance J., et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med318: 1714, 1988 .
120.
Minar E., Ehringer H., Ahmadi R., et al. Platelet deposition at angioplasty sites and its relation to restenosis in human iliac and femoropopliteal arteries. Radiology170:767-772, 1989.
